Bradykinin antagonists: new opportunities

The pro-inflammatory, pain producing, and cardiovascular effects of bradyki nin B-2 receptor activation are well characterized. Bradykinin B-1 receptor s also produce inflammation and pain. Therefore, antagonists are expected t o be anti-inflammatory/analgesic drugs. Other exploitable clinical opportun ities may exist. The newly discovered non-peptide B-2 receptor antagonists and the equivalent B-1 receptor pharmacological agents, which are in the pi peline, are suitable preclinical tools to properly evaluate potential utili ties.